A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., le Roux, Carel W., Violante Ortiz, Rafael, Jensen, Christine Bjørn, Wilding, John P.H.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1411892

Cited by (1,037)

Items 801–900 of 1,037

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Michał Nicze, Adrianna Dec, Maciej Borówka, Damian Krzyżak, Aleksandra Bołdys, Łukasz Bułdak, Bogusław Okopień · 2024 · International Journal of Molecular Sciences
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity
Aikaterini Motso, Benjamin Pelcman, Anastasia Kalinovich, Nour Aldin Kahlous, Muhammad Hamza Bokhari, Nodi Dehvari, Carina Halleskog, Erik Rollman Waara, Jasper M. A. de Jong, Elizabeth Cheesman et al. · 2025 · Cell
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
John W. Ostrominski, ALICE Y.Y. CHENG, Adam J. Nelson, Brendon Lange Neuen, Naveed A. Sattar, Katherine R Tuttle, Muthiah Vaduganathan · 2025 · The Lancet
Genetics of metabolic traits in Greenlanders: lessons from an isolated population
Mette Korre Andersen, Torben F. Hansen · 2018 · Journal of Internal Medicine
Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Yoshifumi Saisho · 2018 · Endocrine Metabolic & Immune Disorders - Drug Targets
Current Long-Term Pharmacotherapies for the Management of Obesity
Bo-Yeon Kim, Seon Mee Kang, Jee‐Hyun Kang, Kyoung Kon Kim, BomTaeck Kim, Seung Jun Kim, Yang‐Hyun Kim, Jung Hwan Kim, Jae Hyun Kim, Ga Eun Nam et al. · 2020 · Journal of Obesity & Metabolic Syndrome
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Lee, Seung Eun, Lee, Nam Young, Kim, Se Hyun, Kim, Kyoung-Ah, Kim, Yong Sik · 2021 · Psychiatry Research
An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Connor Enright, Elizabeth Thomas, David R. Saxon · 2023 · Journal of the Endocrine Society
Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Alejandra Cornejo-Estrada, Carlos Nieto-Rodríguez, Darwin A. León‐Figueroa, Emilly Moreno-Ramos, Cielo Cabanillas-Ramirez, Joshuan J. Barboza · 2023 · Children
Fat mass, weight and body shape changes at menopause – causes and consequences: a narrative review
Anna J. Fenton, C. Smart, L. Goldschmidt, Vanessa Price, J. Scott · 2023 · Climacteric
The Fat Kidney
Ludovica Verde, Stefania Lucà, Simona Cernea, Cem Sulu, Volkan Yumuk, Trond Geir Jenssen, Silvia Savastano, Gerardo Sarno, Annamaria Colao, Luigi Barrea et al. · 2023 · Current Obesity Reports
Pharmacotherapy before and after bariatric surgery
Khaled A. Alabduljabbar, Carel Wynand le Roux · 2023 · Metabolism
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
Goldenberg, Ronald M., Gilbert, Jeremy D., Manjoo, Priya, Pedersen, Sue D., Woo, Vincent C., Lovshin, Julie A. · 2024 · Obesity Reviews
Glucagon‐like peptide‐1 drives energy metabolism on the synaptic highway
Ji Liu, Zhiping P. Pang · 2016 · FEBS Journal
Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu · 2016 · Expert Opinion on Drug Metabolism & Toxicology
The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults
Juan Sun, Zhen Liu, Zimu Zhang, Ziyang Zeng, Weiming Kang · 2022 · Frontiers in Nutrition
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G. · 2020 · Obesity Science & Practice
The Societal Value of Broader Access to Antiobesity Medications
Kabiri, Mina, Sexton Ward, Alison, Ramasamy, Abhilasha, van Eijndhoven, Emma, Ganguly, Rahul, Smolarz, B. Gabriel, Zvenyach, Tracy, Goldman, Dana P., Baumgardner, James R. · 2020 · Obesity
Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder
Zhu, Changliang, Li, Hailiang, Kong, Xuerui, Wang, Yezhong, Sun, Tao, Wang, Feng · 2022 · Frontiers in Pharmacology
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, Vignesh, Patel, Sarang, Kidambi, Srividya · 2017 · Nutrition in Clinical Practice
New approaches to triglyceride reduction: is there any hope left?
Filtz, Annalisa, Parihar, Siddhant, Greenberg, Garred S., Park, Christine M., Scotti, Andrea, Lorenzatti, Daniel, Badimon, Juan J, Soffer, Daniel E., Toth, Peter P., Lavie, Carl J. et al. · 2024 · American Journal of Preventive Cardiology
Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity
Hagan, Scott, Nelson, Karin · 2023 · Journal of General Internal Medicine
Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake
Carolina R. Cawthon, Ginger D. Blonde, A. Valentina Nisi, Haley M Bloomston, Belle Krubitski, Carel Wynand le Roux, Alan C. Spector · 2023 · Journal of the Endocrine Society
Evolving Approaches for Pharmacological Therapy of Obesity
Ariana M. Chao, Simeon I. Taylor, Molly Moore, Anastassia Amaro, Thomas A. Wadden · 2024 · The Annual Review of Pharmacology and Toxicology
Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials
Hon Jen Wong, Keith Zhi Xian Toh, Yao Hao Teo, Yao Neng Teo, Mark Y. Chan, Leonard L.L. Yeo, Pei Chia Eng, Benjamin Yong‐Qiang Tan, Xin Zhou, Qing Yang et al. · 2024 · Journal of Hypertension
GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction
Sumanth Khadke, Ashish Kumar, Ammar W. Bhatti, Sourbha S. Dani, Sadeer G Al-Kindi, Khurram Nasir, Salim S. Virani, Jagriti Upadhyay, Dinamarie Cruz Garcia-Banigan, Sonu Abraham et al. · 2024 · Journal of Cardiac Failure
Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review
Sarah Price, Alison J Nankervis · 2025 · Archives of Gynecology and Obstetrics
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline Margaret Apovian, Shagun Bindlish, Jonathan P. Bonnet, Winfield Scott Butsch, Sandra Michelle Christensen, Eugenia Gianos et al. · 2025 · Obesity Pillars
Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization
Vidhi Singh, Jia Miin Sun, Susan C. Cheng, Alan C. Kwan, Amanda Velazquez · 2025 · Advances in Therapy
Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults
G. Caleb Alexander, Xuya Xiao, Sophie Dilek, Sydney V. Lewis, Qilin Deng, Minji Kim, Dami Bolanle, Ian J Saldanha, Hemalkumar B. Mehta · 2026 · JAMA Internal Medicine
Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
Alexander D. Kokkinos, Dimitrios Tsilingiris, Carel Wynand le Roux, Francesco Rubino, Christos Socrates Mantzoros · 2019 · Metabolism
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Κλεοπάτρα Αλεξιάδου, Tricia Tan · 2020 · Current Diabetes Reports
Type 2 Diabetes Remission with Significant Weight Loss: Definition and Evidence-Based Interventions
Jung Hae Ko, Tae Nyun Kim · 2022 · Journal of Obesity & Metabolic Syndrome
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity
Rie Yazawa, Masahiro Ishida, Yesilda Balavarca, Anita M. Hennige · 2023 · Diabetes Obesity and Metabolism
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
Wong, Nathan D., Karthikeyan, Hridhay, Fan, Wenjun · 2025 · Cardiovascular Drugs and Therapy
Glucagon‐like peptide‐1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism
Ke Lin, Chunyan Dong, Binyan Zhao, Bailing Zhou, Yang Li · 2023 · MedComm
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight
Bruno A. Grassi, María Teresa Onetto, Camila Sánchez, Nicole Tapia, Francisca Mena Salas · 2024 · Diabetes Research and Clinical Practice
How Ethical Is Our Current Delivery of Care to Patients with Severe and Complicated Obesity?
Hilary C. Craig, Carel Wynand le Roux, Fiona Keogh, Francis Martin Finucane · 2018 · Obesity Surgery
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Carolyn T. Bramante, Sarah J. Raatz, Eric Morris Bomberg, Megan O. Bensignor, Justin R. Ryder · 2020 · Frontiers in Endocrinology
Patient Characteristics Associated with Receipt of Prescription Weight‐Management Medications Among Veterans Participating in MOVE!
Thomas, Dylan D., Waring, Molly E., Ameli, Omid, Reisman, Joel I., Vimalananda, Varsha G. · 2019 · Obesity
Evaluation of the efficacy of low‐dose liraglutide in weight control among Taiwanese non‐diabetes patients
Chou, Chien‐An, Chuang, Shu‐Fen · 2020 · Journal of Diabetes Investigation
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, Brian, Hu, Miao, Zhang, Yuzhen, Chan, Paul, Liu, Zhong-Min · 2016 · Expert Opinion on Investigational Drugs
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, Clifford J., Flatt, Peter R., Conlon, J. Michael · 2024 · Peptides
Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice
Amodeo, Giovanni, Cuomo, Alessandro, Bolognesi, Simone, Goracci, Arianna, Trusso, Maria A, Piccinni, Armando, Neal, Stephen M, Baldini, Irene, Federico, Eugenio, Taddeucci, Costanza et al. · 2019 · Expert Opinion on Pharmacotherapy
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders
John Olukorode, Dolapo A Orimoloye, Nwachukwu O Nwachukwu, Chidera N ONWUZO, Praise O. Oloyede, Temiloluwa Fayemi, Oluwatobi S Odunaike, Petra S Ayobami-Ojo, Nwachi Divine, Demilade J Alo et al. · 2024 · Cureus
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Fatima Ali Raza, Rafiya Altaf, Talha Bashir, Fatima Asghar, Rabiya Altaf, Sohaib Tousif, Aman Goyal, Aisha Mohammed, Mahnoor Faisal Mohammad, Mahfuza Anan et al. · 2024 · Medicine
Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease
Lindsay M. Clarke, Ravi Teja Pasam, Bryn E. Falahee, Pichamol Jirapinyo, Jessica Ravikoff Allegretti, Colleen R. Kelly · 2025 · Digestive Diseases and Sciences
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
Richard J. MacIsaac · 2025 · Future Cardiology
Effect of GLP-1 receptor agonists on body composition
Akhila Panduranga Bhandarkar, Sowrabha Bhat, Nitin Kapoor · 2025 · Current Opinion in Endocrinology Diabetes and Obesity
Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis
Paola Gargiulo, Gianluigi Savarese, Carmen D’Amore, Fabiana De Martino, Lars H. Lund, Fabio Marsico, Santo Dellegrottaglie, Caterina Marciano, Bruno Trimarco, Pasquale Perrone Filardi · 2017 · Nutrition Metabolism and Cardiovascular Diseases
Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction
Leon I. Igel, Katherine H. Saunders, Joseph Jack Fins · 2018 · Current Atherosclerosis Reports
Pharmacotherapy in Childhood Obesity
Peter Kühnen, Heike Biebermann, Susanna Wiegand · 2021 · Hormone Research in Paediatrics
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
Luis D’Marco, Valery Morillo, José Luis Górriz, M Suarez, Manuel Nava, Ángel Ortega, Heliana Parra, Nelson Villasmil, Joselyn Rojas, Valmore Bermúdez · 2021 · Journal of Diabetes Research
Síndrome metabólico: revisión de la literatura
María Carolina Fragozo-Ramos · 2022 · Medicina y Laboratorio
Japanese traditional Kampo medicine bofutsushosan improves body mass index in participants with obesity: A systematic review and meta-analysis
Kazushi Uneda, Yuki Kawai, Takayuki Yamada, Akira Kaneko, Ryuji Saito, Lin Chen, Tomoaki Ishigami, Takao Namiki, Tadamichi MITSUMA · 2022 · PLoS ONE
Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
Ides M. Colin, Anne-Catherine Gérard · 2022 · touchREVIEWS in Endocrinology
Approach to the Patient With Hypothalamic Obesity
Ashley Hall Shoemaker, Jaclyn G. Tamaroff · 2022 · The Journal of Clinical Endocrinology & Metabolism
Current and emerging medications for the management of obesity in adults
Rosalind Walmsley, Priya Sumithran · 2023 · The Medical Journal of Australia
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel · 2023 · Obesity
Perivascular adipose tissue in vascular pathologies—a novel therapeutic target for atherosclerotic disease?
Yusuke Adachi, Kazutaka Ueda, Eiki Takimoto · 2023 · Frontiers in Cardiovascular Medicine
Gastrointestinal peptides in eating-related disorders
Kimberly Smith, Timothy H. Moran · 2021 · Physiology & Behavior
Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women
Rodgers, Megan, Migdal, Alexandra L., Rodríguez, Tahereh Ghorbani, Chen, Zsu-Zsu, Nath, Anjali K., Gerszten, Robert E., Kasid, Natasha, Toschi, Elena, Tripaldi, Juliet, Heineman, Brent et al. · 2021 · Frontiers in Endocrinology
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients
Gao, Lijun, Huang, Hong, Zhang, Lu, Zhang, Ningjing, Fu, Yuzhe, Zhu, Dalong, Bi, Yan, Feng, Wenhuan · 2022 · Experimental and Clinical Endocrinology & Diabetes
Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide ‐1‐based therapy
Dash, Satya · 2024 · Diabetes, Obesity and Metabolism
GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty?
Jens T. Verhey, Roman P. Austin, Saad Tarabichi, Benjamin Paul, David G. Deckey, Zachary K. Christopher, Mark J. Spangehl, Joshua S. Bingham · 2025 · The Journal of Arthroplasty
Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
Anna Boglárka Bardóczi, Zsombor Matics, Caner Turan, Bence Szabó, Zsolt Molnár, Péter Hegyi, Veronika Müller, Gábor Horváth · 2025 · Sleep Medicine Reviews
Current and cutting-edge interventions for the treatment of obese patients
Jenanan P. Vairavamurthy, Lawrence Jay Cheskin, Dara L. Kraitchman, Aravind Arepally, Clifford R. Weiss · 2017 · European Journal of Radiology
Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype
Aditya J. Desai, Maoqing Dong, Blake Langlais, Amylou Constance Dueck, Laurence J. Miller · 2017 · American Journal of Clinical Nutrition
Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial
Clare Alexandra Whicher, Hermione Clare Price, Peter Phiri, Shanaya Rathod, Katharine D. Barnard-Kelly, Claire Reidy, Kerensa I. Thorne, Carolyn J Asher, Robert Peveler, Joanne McCarthy et al. · 2019 · Trials
GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy
Aya Shiraki, Jun‐ichi Oyama, Toshiyuki Nishikido, Koichi Node · 2019 · Cardiovascular Diabetology
Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M. Caparrotta, Jack B. Templeton, Thomas A. Clay, Sarah H. Wild, Rebecca M. Reynolds, David John Webb, Helen Martina Colhoun · 2021 · Diabetes Therapy
Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
Mila Sofie Welling, Cornelis J. de Groot, Lotte Kleinendorst, Bibian van der Voorn, Jan Steven Burgerhart, Eline S. van der Valk, Mieke M. van Haelst, Erica L T van den Akker, Elisabeth F. C. van Rossum · 2021 · Clinical Obesity
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Dilek Yazıcı, Hale Yapıcı Eser, Sinem Kucuksarac Kiyici, Seda Sancak, Havva Sezer, Melin Uygur, Volkan Yumuk · 2022 · Obesity Facts
Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis
Inger Smith, EJ Hardy, Stephen Mitchell, Sarah Batson · 2022 · Diabetes Metabolic Syndrome and Obesity
The use of cellulose, chitosan and hyaluronic acid in transdermal therapeutic management of obesity: A review
Gopika Gopan, Jobin Jose, Kartik Bhairu Khot, Akshay Bandiwadekar · 2023 · International Journal of Biological Macromolecules
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, Juan M, Cusi, Kenneth · 2023 · The Journal of Clinical Endocrinology & Metabolism
Seeking satiety: From signals to solutions
Matthias H. Tschöp, Jeffrey M. Friedman · 2023 · Science Translational Medicine
Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review
Alexandre Dréant, Claire Louis Blanchard, David Jacobi · 2024 · Obesity Surgery
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
Sofia Dahlqvist, Elsa Ahlén, Karin Filipsson, Thomas P. Gustafsson, Irl B. Hirsch, Jaakko Tuomilehto, Henrik Imberg, Bo Åhrén, Stig Attvall, Marcus Lind · 2018 · BMJ Open Diabetes Research & Care
Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy
Massimo Volpe, On behalf of the Scientific Societies, Allegra Battistoni, Giovanna Gallo, Speranza Donatella Rubattu, Giuliano Tocci · 2018 · High Blood Pressure & Cardiovascular Prevention
Changes in gut hormones, glycaemic response and symptoms after oesophagectomy
Jessie Andrea Elliott, Neil Gerard Docherty, Conor F. Murphy, Hans‐Georg Eckhardt, Suzanne L. Doyle, Emer M. Guinan, Narayanasamy Ravi, John Vincent Reynolds, Carel Wynand le Roux · 2019 · British journal of surgery
Reducing the Risk of Developing Diabetes
Ally P.H. Prebtani, HARPREET SINGH BAJAJ, Ronald Goldenberg, Yvonne Mullan · 2018 · Canadian Journal of Diabetes
Pharmacological Treatment of Obesity in Older Adults
Žižka, Ondřej, Haluzík, Martin, Jude, Edward B. · 2024 · Drugs & Aging
Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients
Camastra, Stefania, Astiarraga, Brenno, Tura, Andrea, Frascerra, Silvia, Ciociaro, Demetrio, Mari, Andrea, Gastaldelli, Amalia, Ferrannini, Ele · 2017 · Diabetes, Obesity and Metabolism
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
Goldenberg, Ronald M., Ahooja, Vineeta, Clemens, Kristin K., Gilbert, Jeremy D., Poddar, Megha, Verma, Subodh · 2021 · Canadian Journal of Diabetes
The risk of cardiovascular complications with current obesity drugs
Chao, Ariana M., Wadden, Thomas A., Berkowitz, Robert I., Quigley, Kerry, Silvestry, Frank · 2020 · Expert Opinion on Drug Safety
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
Ipsen, Emil Ørskov, Madsen, Kasper S, Chi, Yuan, Pedersen-Bjergaard, Ulrik, Richter, Bernd, Metzendorf, Maria-Inti, Hemmingsen, Bianca · 2020 · Cochrane Database of Systematic Reviews
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Yiwen Liu, Liyun He, Shumeng Han, Fan Ping, Wei Li, Lingling Xu, Huabing Zhang, Yuxiu Li · 2025 · Journal of the American Heart Association
Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity
Hamlet Gasoyan, Mohammad Hesam Alavi, Alexander Zajichek, Nicholas J. Casacchia, Abdullah Al Jabri, James Bena, Xiaoxi Feng, Rickesha L. Wilson, Ricard Corcelles, Winfield Scott Butsch et al. · 2025 · Nature Medicine
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Bernard Chong Eu Khoo, Tricia Tan · 2020 · Journal of Endocrinology
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers
Angela Fitch, Amy Beth Ingersoll · 2020 · Postgraduate Medicine
Obesity in adults: Clinical practice guideline adapted for Chile
Consorcio Chileno para el Estudio de la Obesidad, Yudith Preiss Contreras · 2022 · Medwave
Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial
Cláudia Matta-Coelho, Laurence J. Dobbie, James Crane, Abdel Douiri, Annastazia Learoyd, Olanike Okolo, Spyros Panagiotopoulos, Dimitri J. Pournaras, Sasindran Ramar, Francesco Rubino et al. · 2023 · International Journal of Obesity
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
Miguel Ángel Rubio, Sara Mera Carreiro, Andrés Sánchez-Pernaute, Ana Maria Ramos-Levi · 2023 · Biomedicines
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, Adina Frum, Adriana Aurelia Chiş, Luca Liviu Rus, Stéliana Ghibu, Anca Maria Juncan, Andrei Cătălin Muntean, Antonina Evelina Lazăr et al. · 2024 · Biomedicines
The role of GLP ‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes
Shujah Dar, Abd A. Tahrani, Milan K. Piya · 2015 · Practical Diabetes
Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner
Bark Betzel, Parviez Koehestanie, Jens Homan, Edo Oscar Aarts, Ignace M. C. Janssen, Hans de Boer, Peter J. Wahab, Marcel J. M. Groenen, Frits J. Berends · 2016 · Gastrointestinal Endoscopy
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Patrick J. Knerr, Brian Finan, Vasily M. Gelfanov, Diego Pérez–Tilve, Matthias H. Tschöp, Richard D. DiMarchi · 2017 · Bioorganic & Medicinal Chemistry
Management of Diabetes in Patients Undergoing Bariatric Surgery
Christopher M. Mulla, Harris M. Baloch, Samar Hafida · 2019 · Current Diabetes Reports
Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
Wendy H. Updike, Olivia Pane, Rachel B. Franks, Faizah Saber, Farah Abdeen, Derek D. Balazy, Nicholas W. Carris · 2021 · Drugs